SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD. Shanghai Haohai Biological Technology Co., Ltd. Stock Shanghai S.E.
Equities
688366
CNE100003NX4
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96 CNY | -0.23% |
|
+4.08% | -11.35% |
| Sales 2024 * | 3.09B 427M | Sales 2025 * | 3.52B 486M | Capitalization | 14.35B 1.98B |
|---|---|---|---|---|---|
| Net income 2024 * | 501M 69.2M | Net income 2025 * | 599M 82.74M | EV / Sales 2024 * | 4.64 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.9 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
10.8
x | Employees | 2,158 |
| Yield 2024 * |
-
| Yield 2025 * |
2.83% | Free-Float | 37.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.23% | ||
| 1 week | +4.08% | ||
| Current month | -2.54% | ||
| 1 month | -2.54% | ||
| 3 months | +6.49% | ||
| 6 months | -5.76% | ||
| Current year | -11.35% |
1 week
91.77
97.68
1 month
90.03102.21
Current year
81.10114.88
1 year
77.61120.00
3 years
60.86282.00
5 years
60.86282.00
10 years
60.86282.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Ying Wu
CEO | Chief Executive Officer | 60 | 07-06-30 |
Min Jie Tang
DFI | Director of Finance/CFO | 49 | 16-07-31 |
Chang Zheng Wei
CTO | Chief Tech/Sci/R&D Officer | 45 | 09-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Yi Chen
BRD | Director/Board Member | 42 | 07-01-23 |
Yong Tai Hou
CHM | Chairman | 63 | 07-01-23 |
Jian Ying Wu
CEO | Chief Executive Officer | 60 | 07-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | -0.10% | - | |
| 0.00% | 34 M€ | +1.51% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 96 | -0.23% | 508,096 |
| 24-04-29 | 96.22 | +0.20% | 1,024,352 |
| 24-04-26 | 96.03 | +3.68% | 608,849 |
| 24-04-25 | 92.62 | -0.37% | 497,773 |
| 24-04-24 | 92.96 | +0.16% | 335,785 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
37.85
CNY
Average target price
65.08
CNY
Spread / Average Target
+71.93%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.72% | 184B | |
| -2.60% | 107B | |
| -3.79% | 67.78B | |
| +2.66% | 50.66B | |
| +16.39% | 47.64B | |
| +4.60% | 41.12B | |
| +1.38% | 26.3B | |
| +1.52% | 26.04B | |
| -1.17% | 24.71B |
- Stock Market
- Equities
- 6826 Stock
- 688366 Stock
